<DOC>
	<DOCNO>NCT02997605</DOCNO>
	<brief_summary>The purpose study compare proportion patient could withdraw prednisone hydrocortisone one year progressive decrease GC ( GC taper ) hydrocortisone replacement therapy rheumatoid arthritis remission low disease activity .</brief_summary>
	<brief_title>Comparison Two Strategies Glucocorticoid Withdrawal Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>French multicenter double-blind control parallel-group randomized clinical trial Phase IV assess whether hydrocortisone replacement therapy could increase success rate GC withdrawal one year , patient Rheumatoid Arthritis low disease activity remission , comparison progressive decrease GC ( GC taper ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients ≥ 18 year old . Fulfilling 2010 American College Rheumatology ( ACR ) /EULAR criterion RA . Treated stable dose Synthetic Disease Modifying AntiRheumatic Drugs ( sDMARD ) Biological Disease Modifying AntiRheumatic Drug ( bDMARD ) least 3 month . Who treat prednisone prednisolone least 6 month . With stable dose prednisone prednisolone 5mg/day least 3 month . With DAS28 ≤3.2 least 3 month . Patients health insurance Patients sign write informed consent form . Any chronic condition would need long term corticoid use ( e.g . chronic lung disease ) . Evidence flare within last 3 month . Evidence allergy intolerance hydrocortisone prednisone . Chronic idiopathic , autoimmune clinical adrenal insufficiency . GC joint injection within last 3 month schedule next 3 month . Any disease GC contraindication . Association sultopride live vaccine Significant trauma major surgery within 3 month prior baseline visit . Scheduled surgery next 12 month . Fibromyalgia . Foreseeable poor compliance strategy . Patient condition would prevent participation study completion study procedure , include language limitation . Alcohol and/or drug misuse determine investigator . Pregnancy breastfeed . Patient willing sign inform consent . Juridical Protection DAS28 &gt; 3.2 one month stable dose prednisone 5 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>low disease activity</keyword>
	<keyword>remission</keyword>
</DOC>